September 23, 2026 04:00 ET  | Source: Boehringer Ingelheim Ingelheim, Germany – As part of its global Stop Rabies program, Boehringer Ingelheim, AWARE Germany e.V. and AWARE Trust Zimbabwe are launching a comprehensive rabies-control initiative in the Tsholotsho District of Zimbabwe, one of the most remote and poorest rural areas in the country. Together, the

September 22, 2026 08:00 ET  | Source: Adagene Inc. Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective

September 22, 2026 08:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical cases with LANDMARK Total Knee System, a next-generation knee replacement solution designed to replicate healthy

SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis September 22, 2026 02:15 ET  | Source: Opterion Health AG MUTTENZ, Switzerland, Sept. 22, 2026 (GLOBE NEWSWIRE) — Opterion Health AG, a Swiss clinical-stage biotechnology company developing a novel non-glucose-based solution for peritoneal dialysis, today announced

September 21, 2026 10:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit

September 18, 2026 16:32 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for

September 18, 2026 16:31 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I

September 18, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-‘749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as

September 17, 2026 01:33 ET  | Source: Boehringer Ingelheim Ingelheim, Germany – Boehringer Ingelheim today announced the launch of PED Essentials, a comprehensive e-learning hub designed to help patient organizations generate high-quality patient experience data (PED), share these insights with healthcare stakeholders and analyze existing PED as an evidence base for advocacy. The learning hub comes at

September 16, 2026 08:03 ET  | Source: Royal Philips September 16, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare. SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for

September 16, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing September 16, 2026 00:33 ET  | Source: Cambium Bio Limited SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a

September 15, 2026 05:00 ET  | Source: Hummingbird Bioscience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside Piers Ingram, PhD,

BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA September 14, 2026 17:49 ET  | Source: Curium BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA)

September 14, 2026 08:03 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned